Full-Time

QC Information Systems – Senior Specialist

Qcis

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$100.8k - $151.2k/yr

+ Short-term Incentive Bonus + Equity-based Long-term Incentive Program

Senior

Frederick, MD, USA

Category
Lab & Research
Life Sciences
Requirements
  • Bachelor’s Degree in a science-related field.
  • 5+ years in systems or lab setting.
Responsibilities
  • Perform day-to-day activities and application administration of lab and manufacturing quality control computerized systems, including maintaining static data.
  • Support QC lab functions by providing solutions to a variety of technical problems.
  • Participate in software/computer system validation, IT for software/computer applications, and fulfill all networking and security requirements for enterprise software applications.
  • Facilitate and coordinate training of new and existing local admins, preparing training materials as necessary.
  • Execute protocols, reports, investigations, change management, document authoring, etc., using Veeva on behalf of the department.
  • Support QC information system lifecycle management activities from concept, development, validation, implementation, maintenance, to retirement.
  • Provide audit support to the labs with a strong understanding of administration and data integrity of validated GMP systems.
  • Self-manage tasks and assignments effectively, as well as lead small projects within the team, collaborating with peers, global counterparts, and leadership.
Desired Qualifications
  • Degree in Information Systems/Technology or Biotechnology related field.
  • Experience in information management and/or a scientific lab setting.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatments; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before they reach the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and collaborating with other organizations to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency and innovation.
  • Real-world evidence supports AstraZeneca's drug efficacy and safety demonstrations.
  • Personalized medicine aligns with AstraZeneca's focus on precision oncology treatments.

What critics are saying

  • Class-action lawsuit over Soliris could lead to financial penalties and reputational damage.
  • AI tool for breast cancer screening may face challenges due to minority underrepresentation.
  • Investment in Dunkirk production lines may be affected by changes in French regulations.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing resources with the scientific community.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.